32263-70-0

Usage

Uses

Used in Chemical Research:
6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one is used as a chemical intermediate for the synthesis of other complex molecules. Its unique structure allows it to be a valuable component in the development of new chemical compounds and materials.
Used in Pharmaceutical Industry:
6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one is used as a key building block in the synthesis of pharmaceutical compounds. Its complex structure makes it a promising candidate for the development of new drugs with potential therapeutic applications.
Used in Material Science:
6-(benzyloxy)-3,4-dihydronaphthalen-1(2H)-one is used as a component in the development of advanced materials with specific properties. Its incorporation into material compositions can lead to the creation of novel materials with improved characteristics for various applications.

Upstream product

• 3470-50-6 6-Hydroxy-1-tetralone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 1078-19-9 6-methoxy-3,4-dihydro-1(2H)-naphthalenone 

Downstream Products

• 116885-78-0 butyl 4-benzyloxy-2-(2-cyanoethyl)benzoate 
• 116885-72-4 6-Benzyloxy-3,4-dihydro-[1,2]naphthoquinone 2-oxime 
• 116885-71-3 6-Benzyloxy-3,4-dihydro-[1,2]naphthoquinone 2-oxime 
• 92422-32-7 6-benzyloxy-3,4-dihydro-1,2-naphthalenedione 2-oxime 
• 66361-92-0 6-Benzyloxy-3,4-dihydro-2H-naphthalen-1-one oxime 
• 116885-75-7 E- and Z-4-benzyloxy-2-(2-formylethyl)isopentyl benzoate oxime 
• 583886-96-8 4-(thien-2-yl)-7-benzyloxy-1,2-dihydronaphthalene 
• 66361-75-9 C₂₄H₂₃NO₄S 
• 861930-38-3 6-benzyloxy-2,2-dibromo-3,4-dihydro-2H-naphthalen-1-one 
• 162180-22-5 6'-benzyloxy-3'4'-dihydro-spiro-[cyclopentane-1,2'(1'H)naphthalen]-1'-one 
• 219706-54-4 6-benzyloxy-1-oxo-1,2,3,4-tetrahydronaphtho-2-glyoxylic acid methyl ester 
• 183798-79-0 ethyl 6-benzyloxy-1-oxo-2,3,4-trihydro-2-naphthalenecarboxylate 

Relevant academic research and scientific papers

The evaluation of 1-tetralone and 4-chromanone derivatives as inhibitors of monoamine oxidase

Abstract: Monoamine oxidase (MAO) is of much clinical relevance, and inhibitors of this enzyme are used in the treatment for neuropsychiatric and neurodegenerative disorders such as depression and Parkinson’s disease. The present study synthesises and evaluates the MAO inhibition properties of a series of 33 1-tetralone and 4-chromanone derivatives in an attempt to discover high-potency compounds and to expand on the structure–activity relationships of MAO inhibition by these classes. Among these series, eight submicromolar MAO-A inhibitors and 28 submicromolar MAO-B inhibitors are reported, with all compounds acting as specific inhibitors of the MAO-B isoform. The most potent inhibitor was a 1-tetralone derivative (1h) with IC50 values of 0.036 and 0.0011?μM for MAO-A and MAO-B, respectively. Interestingly, with the reduction of 1-tetralones to the corresponding alcohols, a decrease in MAO inhibition potency is observed. Among these 1-tetralol derivatives, 1p (IC50 = 0.785?μM) and 1o (IC50 = 0.0075?μM) were identified as particularly potent inhibitors of MAO-A and MAO-B, respectively. Potent compounds such as those reported here may act as leads for the future development of MAO-B specific inhibitors. Graphic abstract: The present study describes the MAO inhibitory activities of a series of 1-tetralone and 4-chromanone derivatives. Numerous high-potency MAO-B specific inhibitors were identified.[Figure not available: see fulltext.].

PREVENTIVE AND / OR THERAPEUTIC AGENTS FOR SIP-MEDIATED DISEASES

本發明之課題係提供一種將S1P5受體作動活性相對於S1P1受體作動活性之平衡經改善的化合物作為有效成份的醫藥組成物，以及將該醫藥組成物用於S1P5媒介疾病(例如，神經退化性疾病、多系統萎縮症、巴金森氏病)等之預防及/或治療的醫藥。 包含通式(V)(式中，各基的定義如說明書所載)所示之化合物或其藥學上可容許之鹽、及藥學上可容許之載體的醫藥組成物，係由於改善了S1P5受體作動活性相對於S1P1受體作動活性的平衡，故作為S1P5媒介疾病之預防及/或治療劑有用。 (式中，所有記號如說明書記載) An object

COMPOUND HAVING S1P5 RECEPTOR AGONIST ACTIVITY

Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor has been improved in order to develop a pharmaceutical useful for the treatment of SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. A compound represented by the general formula (V) (wherein, all the symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic agent for S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.

TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS

The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end at least one of a Von Hippel-Lindau ligand, a cereblon ligand, Inhibitors of Apoptosis Proteins ligand, mouse double-minute homolog 2 ligand, or a combination thereof, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

TETRAHYDRONAPHTHALENE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structura

DIHYDRONAPHTHALENE DERIVATIVE

A compound shown by general formula (I) (in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skelet

α-Tetralone derivatives as inhibitors of monoamine oxidase

In the present study, a series of fifteen α-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The α-tetralone derivatives examined are structurally related to a series of chromone (1-benzopyran-4-one) derivatives which has previously been shown to act as MAO-B inhibitors. The results document that the α-tetralones are highly potent MAO-B inhibitors with all compounds exhibiting IC50 values in the nanomolar range (50 values in the nanomolar range (50 value of 4.5 nM with a 287-fold selectivity for MAO-B over the MAO-A isoform, while the most potent MAO-A inhibitor, 6-(3-cyanobenzyloxy)-3,4-dihydro-2H-naphthalen-1-one, exhibits an IC50 value of 24 nM with a 3.25-fold selectivity for MAO-A. Analyses of the structure-activity relationships for MAO inhibition show that substitution on the C6 position of the α-tetralone moiety is a requirement for MAO-A and MAO-B inhibition, and that a benzyloxy substituent on this position is more favourable for MAO-A inhibition than phenylethoxy and phenylpropoxy substitution. For MAO-B inhibition, alkyl and halogen substituents on the meta and para positions of the benzyloxy ring enhance inhibitory potency. It may be concluded that α-tetralone derivatives are promising leads for design of therapies for Parkinson's disease and depression.

α-Tetralone derivatives as inhibitors of monoamine oxidase

In the present study, a series of fifteen α-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B. The α-tetralone derivatives examined are structurally related to a series of chromone (1-benzopyran-4-one) derivatives which has previously been shown to act as MAO-B inhibitors. The results document that the α-tetralones are highly potent MAO-B inhibitors with all compounds exhibiting IC50 values in the nanomolar range (50 values in the nanomolar range (50 value of 4.5 nM with a 287-fold selectivity for MAO-B over the MAO-A isoform, while the most potent MAO-A inhibitor, 6-(3-cyanobenzyloxy)-3,4-dihydro-2H-naphthalen-1-one, exhibits an IC50 value of 24 nM with a 3.25-fold selectivity for MAO-A. Analyses of the structure-activity relationships for MAO inhibition show that substitution on the C6 position of the α-tetralone moiety is a requirement for MAO-A and MAO-B inhibition, and that a benzyloxy substituent on this position is more favourable for MAO-A inhibition than phenylethoxy and phenylpropoxy substitution. For MAO-B inhibition, alkyl and halogen substituents on the meta and para positions of the benzyloxy ring enhance inhibitory potency. It may be concluded that α-tetralone derivatives are promising leads for design of therapies for Parkinson's disease and depression.

Heterobicyclic sphingosine 1-phosphate analogs

Compounds that have agonist activity at one or more of the S1P receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at S1P receptors.

A photo-favorskii ring contraction reaction: The effect of ring size

The effect of ring size on the photo-Favorskii induced ring-contraction reaction of the hydroxybenzocycloalkanonyl acetate and mesylate esters (7a-d, 8a-c) has provided new insight into the mechanism of the rearrangement. By monotonically decreasing the ring size in these cyclic derivatives, the increasing ring strain imposed on the formation of the elusive bicyclic spirocyclopropanone 20 results in a divergence away from rearrangement and toward solvolysis. Cycloalkanones of seven or eight carbons undergo a highly efficient photo-Favorskii rearrangement with ring contraction paralleling the photochemistry of p-hydroxyphenacyl esters. In contrast, the five-carbon ring does not rearrange but is diverted to the photosolvolysis channel avoiding the increased strain energy that would accompany the formation of the spirobicyclic ketone, the "Favorskii intermediate 20". The six-carbon analogue demonstrates the bifurcation in reaction channels, yielding a solvent-sensitive mixture of both. Employing a combination of time-resolved absorption measurements, quantum yield determinations, isotopic labeling, and solvent variation studies coupled with theoretical treatment, a more comprehensive mechanistic description of the rearrangement has emerged.